TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All subjects:~* HIV antibody seronegative (negative HIV rapid test),~* 18 years or older,~* Has a smart phone with access to two-way video call capability,~* Willingness to be contacted for a short call every day for 4 weeks,~* Adequate renal function (creatinine clearance ≥ 60 ml/min estimated by the Cockcroft Creatinine Clearance Formula),~* Provides written informed consent,~For Transgender women:~* Male assigned sex at birth, and self-reported current gender identity as woman or transgender women, or other trans-feminine spectrum identity,~* Current feminizing Hormone Therapy (HT) use for at least 6 months,~For Transgender men:~* Female assigned sex at birth, and self-reported current gender identity as man or transgender man, or other trans-masculine spectrum identity,~* Current masculinizing Hormone Therapy (HT) use for at least 6 months with testosterone~Exclusion Criteria~* Expects to change or discontinue current HT use during the 4 weeks study period,~* Signs of symptoms of acute viral syndrome,~* Use of FTC or TDF in the past 90 days~* Receiving ongoing therapy with any of the following:~AntiRetroviral Therapy, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents~* Renal insufficiency documented as Creatinine Clearance \< 60 ml/min~* For masculine-spectrum identifying persons, positive pregnancy test at screening~* At enrollment, has any other condition or factor that, based on the opinion of the investigator or designee, would preclude provision of informed consent; make participation in the study unsafe; complicate interpretation of study outcome data; or otherwise interfere with achieving the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- TRUVADA DOT (Type: EXPERIMENTAL): one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electroacupuncture for Diminished Ovarian Reserve

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age younger than 40 yr~* 10IU/L ≤ FSH ≤ 40IU/L~* Volunteer to join the research and give the informed consent~Exclusion Criteria:~* A history of ovariectomy, receiving cytotoxic chemotherapy or irradiation~* Reproductive system infection or tumor~* Autoimmune disease~* Amenorrhea due to reproduction abnormality or pregnancy~* Patients can not adhere to treatment due to personal situation~* Patients have taken immunosuppressive agents in past 6 months~* receive treatment for less than 1 week before withdrawal

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- EA group (Type: EXPERIMENTAL): Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
- drug group (Type: ACTIVE_COMPARATOR): Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of ADHD~* Baseline ADHD-RS-IV score \>= 32~* Non-pregnant females of childbearing potential must comply with contraceptive restrictions.~Exclusion Criteria:~* Significantly underweight or morbidly obese~* Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or severe Axis I disorders~* History of seizure, tic disorder, or a current diagnosis and/or family history of Tourette's Disorder~* Females who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for transurethral bladder excision under general anesthesia~* ASA I-III~Exclusion Criteria:~* Bladder outflow obstruction~* Overactive bladder~* End-stage renal disease~* Neurogenic bladder~* Heart failure~* Arrhythmia~* Morbid obesity~* Use of chronic analgesic medication~* Hepatic disease~* Pulmonary disease~* Psychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: EXPERIMENTAL): Sevoflurane will be administered as the maintenance agent of general anesthesia.
- Desflurane (Type: ACTIVE_COMPARATOR): Desflurane will be administered as the maintenance agent of general anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed unresectable or metastatic biliary tract carcinoma (extrahepatic, intrahepatic, or ampulla of Vater) or gallbladder carcinoma Not amenable to combined chemotherapy and radiotherapy CNS metastases that are locally treatable (i.e., lesions treatable with surgery or radiotherapy) allowed if no evidence of progression for at least 4 weeks after completion of treatment~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 3.0 times upper limit of normal (ULN) AST no greater than 5 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic or immunologic therapy No prior biologic or immunologic therapy for metastatic disease No concurrent immunotherapy No colony stimulating factors administered concurrently with first course of study therapy, or within 24 hours prior to subsequent courses Chemotherapy: See Disease Characteristics No prior gemcitabine No prior chemotherapy for metastatic disease At least 6 months since prior chemotherapy used as radiosensitization either in the adjuvant setting or for locally advanced disease No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy to more than 25% of bone marrow No concurrent radiotherapy Surgery: See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- gemcitabine + leucovorin + fluorouracil (Type: EXPERIMENTAL): Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~The following is an abbreviated list of inclusion criteria:~* Adults ≥ 18 years with type 1 or 2 diabetes mellitus~* Decrease in vision determined to be primarily the result of DME in the study eye~* BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye~Exclusion Criteria:~The following is an abbreviated list of exclusion criteria:~* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1~* Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of day 1~* Previous treatment with anti-angiogenic drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc.) within 90 days of day 1~* Active proliferative diabetic retinopathy (PDR) in the study eye~* Uncontrolled diabetes mellitus~* Only 1 functional eye even if that eye is otherwise eligible for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macular Laser Photocoagulation Treatment (Control) (Type: ACTIVE_COMPARATOR): Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
- Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 (Type: EXPERIMENTAL): Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
- Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 (Type: EXPERIMENTAL): Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-50~* Patients who are candidate for abdominal myomectomy~Exclusion Criteria:~* History of previous myomectomy.~* Suspected malignancy~* Patients with preoperative anemia~* Patients using hormonal treatments before the surgery.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Oxytocin infusion (Type: EXPERIMENTAL): Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with multiple myeloma who have received at least 1 prior therapy and who have either responded and later had progressive disease or have progressed during their first therapy (primary refractory) are eligible for the study~* Patients who may have received prior doxorubicin but not more than a cumulative dose of 240 milligram per meter square (mg/m\^2) doxorubicin, DOXIL, or the equivalent amount of another anthracycline (i.e., 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)~* Must have normal cardiac function, as evidenced by a left LVEF within institutional normal limits.~Exclusion Criteria:~* History of treatment with VELCADE or progressive disease while receiving an anthracycline-containing regimen~* No change in disease status during initial therapy~* No treatment for malignancy within past 5 yrs (other than multiple myeloma) or progressive disease while receiving anthracycline-containing regimen~* Non-secretory disease~* Myocardial infarct within past 6 months~* No major surgery in past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VELCADE (bortezomib) monotherapy (Type: ACTIVE_COMPARATOR): Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m\^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
- DOXIL/CAELYX in combination with VELCADE (bortezomib) (Type: EXPERIMENTAL): Bortezomib (VELCADE) 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensive-stage disease~* Measurable disease or lesions~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~Exclusion Criteria:~* Life expectancy of \< 12 weeks~* Current, recent, or planned participation in another experimental drug study~* Ongoing or active infection~* Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within the previous 5 years~* Prior systemic therapy, radiation therapy, or surgery for SCLC~* Inadequate bone marrow function, renal function, or hepatic function~* Serum sodium of \< 120 mg/dL~* Inadequately controlled hypertension~* History of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association Class II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Known central nervous system disease, except for brain metastases treated with whole-brain radiotherapy~* Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to study enrollment~* History of hemoptysis within 4 weeks prior to study enrollment~* Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of a need for a major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1~* History of abdominal fistula or gastrointestinal perforation within 6 months prior to study enrollment~* Serious, non-healing wound, active ulcer, or untreated bone fracture~* Known hypersensitivity to any component of bevacizumab~* Pregnant (positive pregnancy test) or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo+Chemotherapy (Type: PLACEBO_COMPARATOR): Chemotherapy = cisplatin (or carboplatin) + etoposide
- Bevacizumab+Chemotherapy (Type: EXPERIMENTAL): Chemotherapy = cisplatin (or carboplatin) + etoposide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Selenium and Melatonin on Ocular Ischemic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients of Ocular ischemic syndrome (OIS) were the stenosis of the ipsilateral (to the affected eye) internal carotid artery (ICA) was \>50%~* The patients of Ocular ischemic syndrome (OIS) who the ICA blood flow velocity was abnormal;~* Abnormal ocular symptoms and/or signs that could not be explained by other ocular diseases.~Exclusion Criteria:~* The patients who were suffered from other ocular diseases( primary glaucoma, uveitis, age-related macular degeneration, symmetrical proliferative diabetic retinopathy, choroidal detachment, retinal detachment, hereditary eye diseases, ocular tumor, or ocular trauma)

- Gender: ALL
- Minimum Age: 61 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- SELENIUM (Type: OTHER): The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
- MELATONIN (Type: OTHER): The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects should be receiving a stable dose (at least 6 weeks) of any statin and continue on same dose of statin for the duration of this trial.~* Lipids should meet the following criteria on a background treatment with a statin at 2 screening visits that occur at screening and at least 7 days prior to randomization on Day 1:~* Fasting LDL-C greater than or equal to 80 mg/dL (2.31 mmol/L);~* Fasting TG less than or equal to 400 mg/dL (4.52 mmol/L).~* Subject's fasting LDL-cholesterol must greater than or equal to 80 mg/dL (2.31 mmol/L at the initial screening visit, and the value at the second visit within 7 days of randomization must be not lower than 20% of this initial value to meet eligibility criterion for this trial.~Exclusion Criteria:~* Participation in other studies within 3 months before the current study begins and/or during study participation.~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.~* Pregnant females; breastfeeding females; males and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 63 days after last dose of investigational product.~* History of a cardiovascular or cerebrovascular event or procedure (eg, MI, stroke, TIA, angioplasty) during the past 6 months. Congestive heart failure (CHF), NYHA functional classes III or IV.~* Poorly controlled type 1 or type 2 diabetes mellitus (defined as HbA1c \>9%).~* Poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q28d Dosing Arm (Type: EXPERIMENTAL): A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
- Q14d Dosing Arm (Type: EXPERIMENTAL): A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete